Amneal Pharmaceuticals
AMRX | NASDAQ
$21.23
-$0.15 (-0.70%)
At close: Nov 16, 2026, 4:00 PM ET
$21.01
-$0.22 (-1.04%)
After-hours:
Nov 16, 2026, 7:55 PM ET
Amneal Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Chintu Patel | Co-Founder, Co-CEO & Director |
| Chirag K. Patel | Co-Founder, Co-CEO, President & Director |
| Anastasios G. Konidaris | Executive Vice President & Chief Financial Officer |
| Jason Daly | Executive Vice President, Chief Legal Officer & Corporate Secretary |
| Andrew S. Boyer | Executive Vice President and Chief Commercial Officer of Generics & Biosciences |
| Anthony DiMeo | Head/VP of Investor Relations |
| Brandon Skop | Senior Director of Corporate Communications |
| Gregory Sgammato | Senior Vice President of Corporate Development |
| Nikita Shah | Executive Vice President & Chief Human Resources Officer |
| Pranav Mehta | Senior Vice President of Strategic Sourcing & Supply Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K/A | [Amend] Current Report |
| Sep 21, 2026 | 4 | Filing |
| Sep 14, 2026 | 4 | Filing |
| Sep 03, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Sep 02, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
Amneal Pharmaceuticals
| Country | United States |
| IPO Date | May 7, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8,700 |
| CEO | Chirag K. Patel |
Contact Details
400 Crossing Boulevard Bridgewater,
New Jersey 08807 United States
Stock Details
| Ticker Symbol | AMRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723128 |
| CUSIP Number | 03168L105 |
| ISIN Number | US03168L1052 |
| SIC Code | 2834 |
Recent News
- 13 days ago / zacks.comAMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised
- 13 days ago / seekingalpha.comAmneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
- 14 days ago / marketbeat.comWhat Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
- 14 days ago / zacks.comAmneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
- 14 days ago / zacks.comAmneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
- 14 days ago / globenewswire.comAmneal Reports Third Quarter 2026 Financial Results
- 21 days ago / zacks.comAmneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
- 21 days ago / zacks.comIs Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
- 21 days ago / zacks.comImplied Volatility Surging for Amneal Pharmaceuticals Stock Options
- 22 days ago / zacks.comWill Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Add to Watchlist
Select watchlists to add or remove AMRX